Victory Capital Management
ONCT

Victory Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Victory Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-102
Closed -$6K – 3443
2020
Q1 		$6K Buy
+102
New +$7.61K ﹤0.01% 3248
2019
Q4 		– Sell
-23
Closed -$2K – 3432
2019
Q3 		$2K Buy
+23
New +$2.35K ﹤0.01% 3665

Other funds holding ONCT

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.65B AUM 26.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Victory Capital Management's ONCT Position: Q2 2020 in Review

Victory Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2020, closing a stake of 102 shares — an estimated $6K sold.

Victory Capital Management first reported a position in ONCT in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 20 funds tracked by Wall St. Rank hold ONCT as of Q2 2020.

  • Victory Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 102 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2020.
  • 20 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.